HARMONY BIOSCIENCES ANNOUNCES 2022 FUNDING RECIPIENTS OF PATIENTS AT THE HEART AND PROGRESS AT THE HEART AWARD PROGRAMS

Rhea-AI Summary

On September 22, 2022, Harmony Biosciences (NASDAQ: HRMY) announced its 2022 funding recipients for the Patients at the Heart and Progress at the Heart award programs on World Narcolepsy Day. Over the past four years, these programs have awarded a total of $380,000 to nonprofit organizations aimed at supporting people with rare neurological diseases. Recipients this year focus on enhancing community health literacy, creating peer support initiatives, and raising awareness for sleep disorders.

Positive

• Total funding for the Patients at the Heart and Progress at the Heart programs has reached $380,000 over four years.
• The funding recipients represent diverse organizations with innovative, patient-centric initiatives.

Negative

• None.

PLYMOUTH MEETING, Pa., Sept. 22, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced on the fourth annual World Narcolepsy Day, the funding recipients of its Patients at the Heart and Progress at the Heart award programs.

The Patients at the Heart program, which launched in 2019, underscores Harmony's ongoing commitment to support the comprehensive needs of people affected by rare neurological diseases. Over the last four years, the program has awarded numerous nonprofit organizations that are working to support and address the challenges of people living with sleep disorders and rare neurological diseases who experience excessive daytime sleepiness (EDS).

In 2021, Harmony initiated the Progress at the Heart program. This award funds innovative programs that address health disparities and inequities in rare neurological disease and sleep disorder communities. Combined with the Patients at the Heart awards, total funding for these two programs has now increased to $380,000 in over the last four years.

"Combining empathy with innovation to improve the lives of people living with rare neurological diseases is a mission that drives everyone at Harmony Biosciences," said Cate McCanless, Chief Corporate Affairs Officer. "In recognition of World Narcolepsy Day, we are pleased to announce this year's recipients of the Patients at the Heart and Progress at the Heart award programs. This diverse group of organizations have each developed new and innovative patient-centric initiatives to help address the unique needs of people living with rare neurological diseases. We look forward to the positive impact these programs will create for patients, caregivers and communities."

The following organizations were chosen as the 2022 Patients at the Heart award recipients:

• Muscular Dystrophy Association: MDA Access Workshops: Access to Coverage
  MDA Access Workshops are a self-paced community learning and support series focused on increasing community health literacy, empowerment, and self-advocacy. The funding will allow for the expansion of MDA Access Workshops and the addition of a new program, Access to Coverage, that will provide an overview of obtaining insurance coverage for medical equipment and assistive devices.
  
  
• Hypersomnia Foundation: #UNITE Beyond Sleepy – An Interactive Forum for Peer-to-Peer Relational Connections
  Establishing the #UNITE program to foster peer-to-peer support for individuals with hypersomnia disorders to connect and share personal challenges.
  
  
• KLS Foundation: Strategic Communications for Awareness
  Increasing outreach and communication with the Kleine-Levin Syndrome community to raise awareness of the condition, build community and support systems, and facilitate initial patient participation in medical studies. The group aims to complete these goals through the development of resources and support opportunities, website and social media updates, and improvements of their patient registry.
  
  
• Prader-Willi Syndrome Association | USA: Caregiver Retreat
  This event will offer up to thirty parents/caregivers an opportunity to attend a three-day, two-night event providing parents/caregivers with new skills to provide care for their loved one with Prader-Willi syndrome and develop their own self-care practices, including meaningful in-person peer connections.
  
  
• PWN4PWN: TechSoup
  Providing people living with narcolepsy or idiopathic hypersomnia six months of education in the form of webinars and forums in service to PWN4PWN's advocacy mission.

The following organizations and programs were chosen as the 2022 Progress at the Heart award recipients:

• World Sleep Society: Ensuring Equity in the International Sleep Medicine Exam – An Inclusionary Imperative
  The World Sleep Society Sleep Medicine Examination is designed to cover many aspects of sleep science, extant practice guidelines, diagnostic nosology, presentation and associated features of sleep disorders, epidemiology of sleep disorders, clinical pharmacology, behavioral therapeutics, instrumentation, methodology, and sleep health. This funding will increase global access to the International Sleep Medicine Examination through the creation of an online testing platform and scholarships for application fees.
  
  
• Sleep Consortium: Disparity Task Force Initiative – An Inclusive Approach to Patient-Owned Data Collection
  This initiative will create a Task Force comprised of individuals representing Black and Hispanic American communities diagnosed with various sleep disorders. The Task Force will concentrate on identifying barriers their communities face in collecting data in patient-owned platforms, consenting to data sharing practices, and understanding governance issues.
  
  
• Columbia University, Division of Cardiology: "REST: Reinforcing Essentials of Sleep for Teens" in a Diverse Population of High School Students in New York City
  A 12-week behavioral and educational program for high school students in the Washington Heights community of New York City that aims to raise awareness of the importance of healthy sleep for the prevention of cardiovascular disease and other chronic diseases.
  
  
• American Academy of Neurology (AAN) Institute: Diversity Leadership Program
  Diversity in the workforce is critical to cultivating trust in underrepresented communities. The Diversity Leadership Program is an intensive program that identifies, orients, and cultivates underrepresented minority neurologists into future leaders of the American Academy of Neurology and the greater field of neurology and helps to increase access to minority neurologists in communities where there is limited representation.

Harmony's Patients at the Heart award program supports nonprofit organizations. To receive funding, applications must focus on one or more of the following categories:

• Programs that support persons with rare neurological diseases to live fuller, more engaged lives
• Programs that address the psychosocial challenges faced by persons with sleep disorders or rare neurological diseases who experience EDS, or their caregivers
• Programs that improve the overall support of family members of persons living with rare neurological diseases
• Creation of educational materials to increase awareness and decrease time to diagnosis of rare neurological diseases

Harmony's Progress at the Heart award program supports nonprofit organizations. To receive funding, applications must focus on one or more of the following categories:

• Community Programs: People-centered, community-led programs to improve awareness and treatment in the sleep disorder and rare neurological diseases with sleep deficiencies communities and help achieve greater equality for underrepresented ethnic or other minority groups
• Education: General public and healthcare provider education and programs that increase awareness and decrease time to diagnosis of sleep disorders and rare neurological diseases with sleep deficiencies found in underrepresented ethnic or other minority groups
• Public Health: Creation of or modifications to public policies that impact underrepresented ethnic or other minority groups
• Other proposals that help achieve greater equality within rare neurological disease communities

About Harmony Biosciences 

At Harmony Biosciences, we specialize in developing and delivering treatments for rare neurological diseases that others often overlook. We believe that where empathy and innovation meet, a better life can begin for people living with neurological diseases. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, PA, our team of experts from a wide variety of disciplines and experiences is driven by our shared conviction that innovative science translates into therapeutic possibilities for our patients, who are at the heart of everything we do. For more information, please visit www.harmonybiosciences.com. 

Harmony Biosciences Media Contact: 
Nancy Leone 
215-891-6046 
nleone@harmonybiosciences.com 

Harmony Biosciences Investor Contact: 
Luis Sanay, CFA 
445-235-8386 
lsanay@harmonybiosciences.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/harmony-biosciences-announces-2022-funding-recipients-of-patients-at-the-heart-and-progress-at-the-heart-award-programs-301628976.html

SOURCE Harmony Biosciences

FAQ

What is Harmony Biosciences' recent announcement regarding funding recipients on September 22, 2022?

Harmony Biosciences announced its 2022 funding recipients for the Patients at the Heart and Progress at the Heart award programs, providing a total funding of $380,000 over four years.

What are the main goals of Harmony Biosciences' Patients at the Heart and Progress at the Heart award programs?

The programs support nonprofit organizations focusing on health literacy, community support initiatives, and awareness on rare neurological diseases and sleep disorders.

How much funding has Harmony Biosciences awarded through its Patients at the Heart and Progress at the Heart programs?

Harmony Biosciences has awarded a total of $380,000 through the Patients at the Heart and Progress at the Heart programs since their inception.

What is the significance of September 22 for Harmony Biosciences?

September 22 is World Narcolepsy Day, marking the announcement of funding recipients for Harmony's award programs aimed at supporting individuals with sleep disorders.